Immune treatment for EBV-related conditions
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed or suspected EBV-related condition, such as chronic active EBV or post-transplant lymphoproliferative disease.
- You need to be between 18 and 70 years old (or 2-70 for certain types, but this is a general guide).
- You must have evidence of active EBV, like a high viral load in your blood or positive EBER test.
- You must be generally healthy enough, with adequate organ function (heart, liver, kidneys).
- You must not have active, uncontrolled infections or serious health problems that could make the trial unsafe.
- You must be willing to use effective birth control during treatment and for at least 12 months after finishing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a combination of drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) to treat diseases caused by the Epstein-Barr virus (EBV). The goal is to see if this combination can reduce the virus and improve symptoms.
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
Hear when a new CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.